Novel engineered t cell receptors and immune therapy using the same

Engineered T-cell receptors with modified CDRs enhance the specificity and affinity for the COL6A3 antigen, addressing the need for targeted cancer therapies by improving T cell activation against cancer cells, thereby enhancing immunotherapy efficacy.

JP2024156654APending Publication Date: 2024-11-06IMMATICS BIOTECHNOLOGIES GMBH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024101016
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-11-06
Filing Date
2024-06-24
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current cancer treatments lack drugs that specifically target cancer cells with high specificity, necessitating the development of novel therapies that can selectively recognize and destroy tumor cells.

Method used

Engineering T-cell receptors (TCRs) with modified complementarity determining regions (CDRs) to enhance specificity and affinity for the COL6A3 antigen, allowing for the development of antigen recognition constructs that can be used in immunotherapy to target cancer cells.

Benefits of technology

The engineered TCRs demonstrate improved binding and activation of T cells against cancer cells expressing COL6A3, providing a targeted immune response with increased specificity and efficacy in treating various cancer types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156654000012
    Figure 2024156654000012
  • Figure 2024156654000013
    Figure 2024156654000013
  • Figure 2024156654000014
    Figure 2024156654000014
Patent Text Reader

Abstract

To provide new anti-cancer agents that specifically target molecules highly specific to cancer cells.SOLUTION: The invention provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antigen recognition constructs for the COL6A3 antigen. In particular, the present invention provides novel engineered T cell receptor (TCR)-based molecules that are selective and specific for tumors expressing the antigen COL6A3. The TCRs of the present invention, and COL6A3 antigen-binding fragments derived therefrom, are useful for the diagnosis, treatment, and prevention of cancerous diseases expressing COL6A3. Additionally, nucleic acids encoding the antigen recognition constructs of the present invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognition constructs, and pharmaceutical compositions comprising the compounds of the present invention are provided. [Background technology]

[0002] Collagens are a superfamily of proteins that play a role in maintaining the integrity of various tissues. Collagens are extracellular matrix proteins that have a triple helical domain as their common structural element. Collagen VI is the major structural component of microfibrils. The basic structural unit of collagen VI is a heterotrimer of α1(VI), α2(VI), and α3(VI) collagen chains. The α1(VI) and α2(VI) chains are encoded by the COL6A1 and COL6A2 genes, respectively. The protein encoded by the COL6A3 gene is the α3 subunit of type VI collagen (α3(VI) collagen chain) (Bertini et al., 2002 Eur. J. Paediatr. Neurol 6:193-8). Gene expression of COL6A3 has previously been shown to be associated with breast cancer progression and elevated in colorectal cancer (Smith MJ,et al., “Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification” British journal of cancer.2009;100:1452-1464; Tilman G et al., “Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells” Mol Cancer.2007;6:80), and has been shown to be a prognostic marker for colorectal cancer (Qiao J et al., “Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics” Oncotarget.2015 Oct 6;6(30):29929-29946). The COL6A3 gene is located at 2q37 of the human genome and contains 44 exons.The COL6A3 protein has 3177 amino acids and contains 12 von Willebrand factor type A (vWA) domains, one fibronectin type 3 domain, and one BPTI / Kunitz family serine protease inhibitor (KU) domain.

[0003] The targets of T cell-based immunotherapy correspond to peptide epitopes derived from tumor-associated or tumor-specific proteins presented by molecules of the major histocompatibility complex (MHC). These tumor-associated antigens (TAA) can be peptides derived from all protein classes, such as enzymes, receptors, transcription factors, etc., that are expressed in each tumor cell and are usually upregulated compared to unaltered cells of the same origin.

[0004] Certain elements of the cellular immune response can selectively recognize and destroy tumor cells. Isolation of tumor antigen-specific T cells from tumor-infiltrating cell populations or from peripheral blood suggests that such cells play an important role in the innate immune defense against cancer. In particular, CD8+ T cells that recognize class I molecules of major histocompatibility complex (MHC)-carrying peptides, usually of 8-10 amino acid residues, derived from proteins or defective ribosomal products (DRiPs) located in the cytosol play a key role in this response. MHC molecules in humans are also called human leukocyte antigens (HLA).

[0005] TCRs are heterodimeric cell surface proteins of the immunoglobulin superfamily that are associated with the invariant protein of the CD3 complex, which is involved in mediating signal transduction. TCRs exist as αβ and γδ heterodimers, which are structurally similar but have quite different anatomical locations and possibly functions. The extracellular portion of the native heterodimeric αβTCR consists of two polypeptide chains, each of which has a membrane-proximal constant domain and a membrane-distal variable domain. Each of the constant and variable domains contains an intrachain disulfide bond. The variable domain contains a highly polymorphic loop, similar to the complementarity determining region (CDR) of an antibody. The use of TCR gene therapy overcomes some of the current hurdles. It endows the patient's own T cells with the desired specificity, allowing the generation of sufficient numbers of T cells in a short period of time and avoiding their exhaustion. TCRs can be transduced into T cells with central memory or stem cell characteristics, which may ensure better persistence and function upon transfer. TCR-engineered T cells are infused into cancer patients rendered lymphopenic by chemotherapy or irradiation, allowing efficient engraftment but preventing immunosuppression. Summary of the Invention [Problem to be solved by the invention]

[0006] Despite progress in the development of molecularly targeted drugs for cancer treatment, there remains a need in the art to develop new anti-cancer agents that specifically target highly specific molecules in cancer cells. [Means for solving the problem]

[0007] The present specification addresses this need by providing novel engineered COL6A3 TCRs, respective recombinant TCR constructs, nucleic acids, vectors, and host cells that specifically bind to the COL6A epitope as disclosed; and methods of using such molecules in the treatment of cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] In a first aspect, the object of the present invention is solved by an antigen recognition construct comprising a first domain comprising three complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 5 (CDRa1), 6 (CDRa2) and 7 (CDRa3) and a second domain comprising three complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 13 (CDRb1), 14 (CDRb2) and 15 (CDRb3), wherein at least one of said complementarity determining regions is replaced with at least one sequence selected from the group of a) SEQ ID NO: 26 (CDRa1-mut1), and SEQ ID NOs: 37 to 49 (CDRb1-mut1 to CDRb1-mut13), preferably SEQ ID NO: 40, and b) mutant sequences of SEQ ID NOs: 26, and SEQ ID NOs: 37 to 49, preferably SEQ ID NO: 40, comprising conservative amino acid exchanges.

[0009] In another embodiment, the CDRa1 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:5.

[0010] In another embodiment, the CDRa2 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:6.

[0011] In another embodiment, the CDRa3 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:7.

[0012] In another embodiment, CDRb1 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:13.

[0013] In another embodiment, the CDRb2 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:14.

[0014] In another embodiment, the CDRb3 of the antigen recognition construct may have at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the amino acid sequence set forth in SEQ ID NO:15.

[0015] In the context of the present invention, the inventors have identified improved engineered versions of the COL6A3 TCR R4P3F9 comprising mutated CDR1 sequences in the alpha and beta chains that improve the stability, recognition and selectivity of the parent R4P3F9. These mature TCR variants are selected in a two-stage process, where the first stage selects for the stability of the variants and the second stage selects for the affinity of the variants (see Examples). While the TCRs of the present invention comprise mutated CDR1 regions, CDR2 and or CDR3 may also be mutated to increase binding affinity / specificity and / or selectivity, and such mutated CDRs may ideally be included in existing constructs.

[0016] Affinity maturation identifies variants that retain or even improve specificity while still retaining HLA-A specificity. * 02 / COL6A3 peptide.Compared to the parental TCR C-1 (R4P3F9 TCR comprising wild-type CDRs, see Table 5), all variants of the invention improved IFN-γ release, reaching higher levels already at lower peptide loading concentrations.

[0017] Within the variable domain, CDR1 and CDR2 are found in the variable (V) region of the polypeptide chain, and CDR3 includes part of V and all of the diversity (D) and joining (J) regions. CDR3 is assumed to be the main CDR that is the most variable and is involved in specific and selective recognition of antigen. Surprisingly, some TCR CDR1 also appears to contact peptide, and thus also participates in selective recognition. In this case, without being bound by a particular theory, it appears that mutant CDR1b interacts with position 8 of COL6A3 peptide.

[0018] Natural α-β heterodimeric TCRs have an α chain and a β chain. Each α chain comprises a variable region, a joining region, and a constant region, while the β chain usually also contains a short diversity region between the variable and joining regions, but this diversity region is often considered as part of the joining region. Each variable region comprises three CDRs (complementarity determining regions) embedded in a framework sequence, one of which is a hypervariable region designated CDR3. There are several types of α chain variable (Vα) regions and several types of β chain variable (Vβ) regions, differentiated by their frameworks, by CDR1 and CDR2 sequences, and by partially defined CDR3 sequences. The Vα types are designated in the IMGT nomenclature by a unique TRAV number, and the Vβ types by a unique TRBV number.

[0019] Preferably, the antigen recognition construct of the present invention comprises each of the CDR1-CDR3 of one of the engineered TCR variable regions of the present invention disclosed herein. Preferred are antigen recognition constructs of the present invention comprising at least one, preferably two, mature CDR1 sequences (e.g., αβ and γδ TCRs).

[0020] The CDR variants disclosed herein, particularly the CDR1 variants, may be modified by substitution of one or more residues at different, possibly selective, sites in the peptide chain, unless otherwise specified. Such substitutions are of a conservative nature, and an amino acid is replaced by an amino acid with similar structure and characteristics, such as a hydrophobic amino acid being replaced by another hydrophobic amino acid. Even more conservative substitutions are the replacement of amino acids with the same or similar size and chemical properties, such as the replacement of leucine with isoleucine. In the study of sequence diversity of naturally occurring homologous protein families, certain amino acid substitutions are often tolerated better than others, and these often show a correlation with the similarity of size, charge, polarity and hydrophobicity between the original amino acid and its replacement, which is the basis for the definition of "conservative substitution". Preferred conservative substitutions are defined herein as exchanges within one of the following five groups: Group 1 - small aliphatic, non-polar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2 - polar negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3 - polar positively charged residues (His, Arg, Lys); Group 4 - large aliphatic non-polar residues (Met, Leu, Ile, Val, Cys); and Group 5 - large aromatic residues (Phe, Tyr, Trp).

[0021] A less conservative substitution might involve the substitution of another amino acid with similar characteristics but somewhat different in size, such as the replacement of an alanine with an isoleucine residue.

[0022] The terms "specificity" or "antigen specificity" or "specific for" a given antigen, as used herein, mean that an antigen recognition construct can specifically bind to said antigen, preferably to the COL6A3 antigen, more preferably with high avidity, when the antigen is presented by HLA, preferably HLA A2. For example, a TCR as an antigen recognition construct may be considered to have "antigenic specificity" for a COL6A3 antigen if, upon co-culture with HLA A2 target cells pulsed with low concentrations of a COL6A3 antigen, such as the COL6A3 epitopes and antigens provided below, T cells expressing the TCR in response to COL6A3 secrete at least about 200 pg / ml or more (e.g., 250 pg / ml or more, 300 pg / ml or more, 400 pg / ml or more, 500 pg / ml or more, 600 pg / ml or more, 700 pg / ml or more, 1000 pg / ml or more, 2,000 pg / ml or more, 2,500 pg / ml or more, 5,000 pg / ml or more) of interferon gamma (IFN-γ) (e.g., about 10 -11 mol / l, 10 -10 mol / l, 10 -9 mol / l, 10 -8 mol / l, 10 -7 mol / l, 10 -6 mol / l, 10 -5 Alternatively, or in addition, a TCR may be considered to have "antigen specificity" for COL6A3 if cells expressing the TCR secrete at least twice the non-transduced background level of IFNγ upon co-culture with target cells pulsed with low concentrations of COL6A3 antigen. Such "specificity" may be analyzed, for example, using ELISA.

[0023] In an alternative or additional embodiment of the invention, the antigen recognition construct is stable and capable of specifically and / or selectively binding to the COL6A3 antigen; preferably the COL6A3 antigen is a protein epitope or peptide having the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof. The variant is a deletion, addition, insertion or substitution of amino acids at no more than three, preferably at no more than two, most preferably at no more than one amino acid position.

[0024] The term "selectivity" or "selectively recognizes / binds" is understood to refer to the property of an antigen recognition construct, such as a TCR or an antibody, that selectively recognizes or binds, preferably, only one specific epitope, and preferably exhibits no or substantially no cross-reactivity to other epitopes. Preferably, "selectivity" or "selectively recognizes / binds" refers to an antigen recognition construct (e.g., a TCR) that selectively recognizes or binds, preferably, only one specific epitope, and preferably exhibits no or substantially no cross-reactivity to other epitopes, said epitope being unique to one protein, such that the antigen recognition construct exhibits no or substantially no cross-reactivity to other epitopes and other proteins.

[0025] The antigen recognizing the construct according to the invention is preferably selected from an antibody, or a derivative or fragment thereof, a bispecific molecule, or a T-cell receptor (TCR), or a derivative or fragment thereof. An antibody or TCR derivative or fragment of the invention should preferably maintain the antigen binding / recognition capacity of the parent molecule, in particular its specificity and / or selectivity as explained above.

[0026] In one embodiment of the present invention, the engineered TCR of the present invention can recognize the COL6A3 antigen in a major histocompatibility complex (MHC) class I-dependent manner. "MHC class I-dependent manner" as used herein means that the TCR induces an immune response upon binding to the COL6A3 peptide antigen within the context of an MHC class I molecule. The MHC class I molecule can be any MHC class I molecule known in the art, such as, for example, an HLA-A molecule. In a preferred embodiment of the present invention, the MHC class I molecule is an HLA-A2 molecule.

[0027] The present invention provides both single chain antigen recognizing constructs and two chain antigen recognizing constructs as well as other mutant molecules. The present invention particularly provides engineered TCRs, or fragments or derivatives thereof, as antigen recognizing constructs. Engineered TCRs are preferably of human origin and are generated from human TCR loci and are therefore understood to comprise human TCR sequences. Furthermore, the TCRs of the present invention are characterized as affinity matured TCRs that can specifically and selectively recognize the COL6A3 peptide antigen.

[0028] Another embodiment of the present invention additionally or alternatively provides an antigen recognition construct as described above which induces an immune response, preferably characterized by an increase in interferon (IFN) gamma levels.

[0029] The TCRs of the present invention may be provided as single chain α or β, or γ and δ, molecules, or alternatively as two-chain constructs composed of both α and β chains, or both γ and δ chains.

[0030] Most preferably, in some additional embodiments, the present disclosure refers to an antigen recognition construct comprising any one, two or all of the CDR1-CDR3 regions of the engineered TCR chains disclosed herein (see Table 1). Antigen recognition constructs comprising native or engineered CDR sequences with three, two and preferably only one modified amino acid residue may be preferred. The modified amino acid residues may be selected from amino acid insertions, deletions or substitutions. Most preferably, the three, two, preferably one modified amino acid residues are the first or last amino acid residues of the respective CDR sequence. When the modifications are substitutions, in some embodiments, it is preferred that the substitutions are conservative amino acid substitutions.

[0031] The TCR of the present invention may further comprise a constant region derived from any suitable species, such as any mammal, such as human, rat, monkey, rabbit, donkey, or mouse. In one embodiment of the present invention, the TCR of the present invention further comprises a human constant region. In some preferred embodiments, the constant region of the TCR of the present invention may be slightly modified, for example, by the introduction of heterologous sequences, preferably mouse sequences, which may increase TCR expression and stability. In addition, further stabilizing mutations known from the state of the art (e.g., DE 102016123893.7), such as the substitution of unfavorable amino acids in the V region and / or the introduction of disulfide bridges between the TCR C domains and the removal of unpaired cysteines, may be introduced.

[0032] As used herein, the terms "mouse" or "human" when referring to an antigen recognition construct, or a TCR, or any component of a TCR as described herein (e.g., the complementarity determining regions (CDRs), variable region, constant region, α chain, and / or β chain), refer to a TCR (or component thereof) derived from a mouse or human unrearranged TCR locus, respectively.

[0033] In one embodiment of the invention, a chimeric TCR is provided, wherein the TCR chain comprises sequences from multiple species. Preferably, the TCR of the invention may comprise an alpha chain, comprising a human variable region of the alpha chain and a mouse constant region, for example a mouse TCR alpha chain.

[0034] In one embodiment, the TCR of the present invention is a human TCR, comprising a human variable region according to the above embodiments and a human constant region.

[0035] The TCR of the present invention may be provided as a single chain TCR (scTCR). The scTCR may comprise a polypeptide of the variable region of a first TCR chain (e.g., an α chain) and a polypeptide of the entire (full-length) second TCR chain (e.g., a β chain), or vice versa. Additionally, the scTCR may optionally comprise one or more linkers linking two or more polypeptides together. The linker may be, for example, a peptide that binds two single chains together, as described herein. Also provided are scTCRs of the present invention fused to human cytokines such as IL-2, IL-7 or IL-15.

[0036] The antigen recognition construct according to the present invention may also be provided in the form of a multimeric complex comprising at least two scTCR molecules, each fused to at least one biotin moiety, and the scTCRs interconnected by biotin-streptavidin interactions, allowing the multimeric complex to form. Similar approaches to generate multimeric TCRs are also possible and are included in the present disclosure. Higher order multimeric complexes comprising more than two scTCRs of the present invention are also provided.

[0037] For the purposes of the present invention, a TCR is a moiety having at least one TCR alpha or gamma and / or TCR beta or delta variable domain. Generally, they comprise both a TCR alpha variable domain and a TCR beta variable domain. They may be alpha beta heterodimers or in single chain form. For use in adoptive therapy, an alpha beta heterodimeric TCR may be transfected as a full-length chain, for example, having both a cytoplasmic domain and a transmembrane domain. If desired, an introduced disulfide bond may be present between the residues of the respective constant domains.

[0038] In a preferred embodiment, the antigen recognition construct is a human TCR, or a fragment or derivative thereof. A human TCR or a fragment or derivative thereof is a TCR that comprises more than 50% of the corresponding human TCR sequence. Preferably, only a small part of the TCR sequence is of artificial origin or originates from other species. However, it is known that chimeric TCRs, such as those that are of human origin and have mouse sequences in their constant domains, are advantageous. Therefore, TCRs according to the present invention that contain mouse sequences in the extracellular part of their constant domains are particularly preferred.

[0039] Therefore, it is also preferred that the antigen recognition construct of the present invention is capable of recognizing its peptide antigen in a human leukocyte antigen (HLA)-dependent manner, preferably in an HLA-A02-dependent manner. The term "HLA-dependent manner" in the context of the present invention means that the antigen recognition construct binds to an antigen only if the antigenic peptide is presented by said HLA.

[0040] The antigen recognition construct according to the present invention, in one embodiment, preferably induces an immune response, preferably characterized by an increase in interferon (IFN) gamma levels.

[0041] The term "polypeptide" as used herein includes oligopeptides and refers to a single chain of amino acids linked by one or more peptide bonds. In relation to the polypeptides of the present invention, a functional portion may be any portion comprising consecutive amino acids of the TCR (or functional variant thereof) of which it is a part, provided that the functional portion specifically binds to the COL6A3 antigen, preferably as disclosed in Table 1 herein. The term "functional portion", when used in relation to a TCR (or functional variant thereof), refers to any portion or fragment of the TCR (or functional variant thereof) of the present invention, which portion or fragment maintains the biological activity of the TCR (or functional variant thereof) of which it is a part (parent TCR or parent functional variant thereof). A functional portion, for example, retains the ability to specifically bind to the COL6A3 antigen (in an HLA-A2-dependent manner) or detect, treat, or prevent cancer to a similar extent, to the same extent, or to a greater extent than the parent TCR (or functional variant thereof) that encompasses the portion of the TCR (or functional variant thereof).

[0042] The functional portion may comprise additional amino acids at the amino or carboxy terminus of the portion, or at both termini, which additional amino acids are not found in the amino acid sequence of the parent TCR or a functional variant thereof. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, e.g., the ability to specifically bind to the COL6A3 antigen; and / or to detect, treat or prevent cancer. More desirably, the additional amino acids enhance the biological activity compared to the biological activity of the parent TCR or a functional variant thereof.

[0043] As already mentioned above, the binding functionality of the TCR of the present invention may be provided in the framework of an antibody. The term "antibody" in its various grammatical forms is used herein to refer to an immunoglobulin molecule and to refer to an immunologically active portion of an immunoglobulin molecule, i.e. a molecule containing an antigen-binding site or paratope. Such molecules are also referred to as "antigen-binding fragments" of an immunoglobulin molecule. The present invention further provides an antibody or an antigen-binding portion thereof, which specifically binds to an antigen as described herein. The antibody may be any type of immunoglobulin known in the art. For example, the antibody may be of any isotype, e.g., IgA, IgD, IgE, IgG, IgM, etc. The antibody may be monoclonal or polyclonal. The antibody may be a natural antibody, e.g., an antibody isolated and / or purified from a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, etc. Alternatively, the antibody may be a genetically modified antibody, e.g., a humanized antibody or a chimeric antibody. The antibody may be in monomeric or polymeric form.

[0044] The present invention also provides an antigen-binding portion of any of the antibodies described herein. The antigen-binding portion can be any portion having at least one antigen-binding site, such as Fab, F(ab')2, dsFv, scFv, diabodies, and triabodies. Single-chain variable fragment (scFv) antibody fragments consisting of a truncated Fab fragment comprising the variable (V) domain of an antibody heavy chain linked to the V domain of a light antibody chain via a synthetic peptide can be generated using routine recombinant DNA technology techniques. Similarly, disulfide-stabilized variable fragments (dsFv) can be prepared by recombinant DNA technology, although the antibody fragments of the present invention are not limited to these exemplary types of antibody fragments. Antibodies, or antigen-binding portions thereof, can also be modified to comprise detectable labels, such as, for example, radioisotopes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), enzymes (e.g., alkaline phosphatase, horseradish peroxidase), and elemental particles (e.g., gold particles).

[0045] Suitable methods for producing antibodies are known in the art.For example, standard hybridoma methods are described, for example, in Kohler and Milstein, Eur.J.Immunol,5,51 1-519(1976), Harlow and Lane(eds.), Antibodies:A Laboratory Manual, CSH Press(1988), and CA Janeway et al.(eds.), Immunobiology,8th Ed., Garland Publishing, New York, NY(2011)). Alternatively, other methods are known in the art, such as the EBV-hybridoma method (Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), and Roder et al, Methods Enzymol, 121, 140-67 (1986)), the bacteriophage vector expression system (see, e.g., Huse et al., Science, 246, 1275-81 (1989)). Additionally, methods for producing antibodies in non-human animals are described, for example, in U.S. Pat. Nos. 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication No. 2002 / 0197266.

[0046] Some embodiments of the present invention also relate to TCRs or functional fragments and polypeptides thereof, which are soluble TCRs. As used herein, the term "soluble T cell receptor" refers to single chain or heterodimeric truncated variants of native TCRs, comprising at least the variable domains of the TCR α and β chains linked by a polypeptide bond (SEQ ID NOs: 22, 24, 25, and 27). Soluble variants of TCRs usually lack at least the transmembrane and cytosolic domains of the native protein; sometimes, preferably, such soluble constructs do not comprise any constant domain sequences. The soluble T cell receptor constructs of the present invention, in preferred embodiments, comprise constructs consisting of the α and β chain variable domain sequences provided herein linked by a suitable linker sequence. The soluble TCR α and β chain variable domain sequences (amino acids or nucleic acids) may be identical to the corresponding sequences in the native TCR, or may comprise variants of the soluble TCR α and β chain variable domain sequences compared to the corresponding native TCR sequences. The term "soluble T cell receptor" as used herein encompasses soluble TCRs having mutated or non-mutated soluble TCR α and β chain variable domain sequences. Mutations may be in the framework and / or CDR regions of the soluble TCR α and β chain variable domain sequences and may include, but are not limited to, amino acid deletion, insertion, substitution mutations, as well as nucleic acid sequence changes that do not alter the amino acid sequence. Soluble TCRs of the invention in any event retain, or preferentially improve, the binding function of their parent TCR molecules.

[0047] The above problem is further solved by a nucleic acid encoding an antigen recognition construct of the invention, or any of the protein or polypeptide constructs described above. The nucleic acid preferably has (a) a strand encoding an antigen recognition construct according to the invention; (b) a strand complementary to the strand of (a); or (c) a strand that hybridizes under stringent conditions to a molecule according to (a) or (b). Stringent conditions are known to the skilled person, in particular from Sambrook et al., "Molecular Cloning". In addition to that, the nucleic acid optionally has further sequences necessary for expression, in particular in mammalian / human cells, to express the nucleic acid sequence corresponding to the protein. The nucleic acid used may be included in a vector suitable to allow the expression of the nucleic acid sequence corresponding to the polypeptide inside the cell. However, the nucleic acid may also be used to transform antigen presenting cells, which may not be limited to classical antigen presenting cells, such as dendritic cells, so that they themselves produce the corresponding protein on their cell surface.

[0048] "Nucleic acid," as used herein, includes "polynucleotide," "oligonucleotide," and "nucleic acid molecule," and generally refers to a polymer of DNA or RNA, which may be single-stranded or double-stranded, synthesized or obtained from a natural source (e.g., isolated and / or purified), and which may contain natural, non-natural or modified nucleotides, and which may contain natural, non-natural or modified internucleotide linkages, such as phosphoroamidate or phosphorothioate linkages in place of the phosphodiesters found between the nucleotides of unmodified oligonucleotides.

[0049] Preferably, the nucleic acids of the invention are recombinant. As used herein, the term "recombinant" refers to (i) a molecule constructed outside a living cell by linking a natural or synthetic nucleic acid segment to a nucleic acid molecule capable of autonomous replication in a living cell, or (ii) a molecule resulting from replication as described in (i) above. For purposes herein, autonomous replication can be in vitro replication or in vivo replication. The nucleic acid can comprise any nucleotide sequence that encodes any of the TCRs, polypeptides, or proteins described herein, or functional portions or functional variants thereof.

[0050] The present invention further provides a vector comprising the above-mentioned nucleic acid according to the present invention. Desirably, the vector is an expression vector or a recombinant expression vector. The term "recombinant expression vector" in the context of the present invention refers to a nucleic acid construct that allows the expression of mRNA, protein or polypeptide in a suitable host cell. The recombinant expression vector of the present invention can be any suitable recombinant expression vector and can be used to transform or transfect any suitable host. Suitable vectors include, for example, those designed for propagation and expansion, or for expression, or both, such as plasmids and viruses. Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo. Preferably, the recombinant expression vector is a viral vector, such as, for example, a retroviral vector. The recombinant expression vector comprises control sequences, such as transcriptional and translational initiation and termination codons, specific for the type of host cell (e.g., bacterial, fungal, plant, or animal) into which the vector is introduced and in which expression of the nucleic acid of the present invention may be performed. Additionally, the vectors of the present invention may contain one or more marker genes that allow for the selection of transformed or transfected hosts. The recombinant expression vectors may comprise a native or canonical promoter that is operably linked to a nucleotide sequence encoding the construct of the present invention or to a nucleotide sequence that is complementary to or hybridizes with the nucleotide sequence encoding the construct of the present invention. Promoter options include, for example, strong promoters, weak promoters, inducible promoters, tissue-specific promoters, and development-specific promoters. The promoters may be non-viral or viral promoters. The recombinant expression vectors of the present invention may be designed for either transient expression, stable expression, or both. Also, the recombinant expression vectors may be made for constitutive or inducible expression.

[0051] The present invention also relates to a host cell comprising an antigen recognition construct according to the present invention. In particular, the host cell of the present invention comprises a nucleic acid or vector as described herein above. The host cell may be a eukaryotic cell, such as, for example, a plant, an animal, a fungus, or an algae, or a prokaryotic cell, such as, for example, a bacterium or a protozoan. The host cell may be a cultured cell or a primary cell, i.e. a cell directly isolated from an organism, such as, for example, a human. The host cell may be an adherent cell or a suspension cell, i.e. a cell that grows in suspension. For producing recombinant TCRs, polypeptides, or proteins, the host cell is preferably a mammalian cell, such as, for example, a Chinese Hamster Ovary (CHO) cell. Most preferably, the host cell is a human cell. Although the host cell may be any cell type, derived from any tissue type, and at any developmental stage, the host cell is preferably a peripheral blood leukocyte (PBL) or a peripheral blood mononuclear cell (PBMC). More preferably, the host cell is a T cell. The T cells can be any T cells, e.g., cultured T cells, e.g., primary T cells; or T cells from cultured T cell lines, e.g., Jurkat, SupT1; or T cells obtained from a mammal, preferably T cells or T cell precursors from a human patient. If obtained from a mammal, the T cells can be obtained from a number of sources, including, but not limited to, blood, bone marrow, lymph nodes, thymus, or other tissues or fluids. The T cells can also be enriched or purified. Preferably, the T cells are human T cells. More preferably, the T cells are T cells isolated from a human. The T cells can be any T cell type and at any stage of development, including, but not limited to, CD4 positive and / or CD8 positive, CD4 positive helper T cells, e.g., Th1 and Th2 cells, CD8 positive T cells (e.g., cytotoxic T cells), tumor infiltrating cells (TILs), memory T cells, naive T cells, and the like. Preferably, the T cells are CD8 positive T cells or CD4 positive T cells.

[0052] Preferably, the host cell of the present invention is a lymphocyte, preferably a T lymphocyte, such as a CD4-positive or CD8-positive T cell. The host cell is more preferably a tumor-reactive T cell specific for a COL6A3-expressing tumor cell.

[0053] A further aspect of the present invention relates to an antigen recognition construct, a nucleic acid, a vector, a pharmaceutical composition and / or a host cell disclosed herein for use in medicine. In a preferred embodiment, the use in medicine includes use in the diagnosis, prevention and / or treatment of a tumor disease, such as a malignant or benign tumor disease. The tumor disease is, for example, a tumor disease characterized by the expression of COL6A3 in cancer or tumor cells of said tumor disease.

[0054] With respect to the aforementioned medical uses of the antigen recognition constructs and other substances derived therefrom, the cancers to be treated and / or diagnosed include acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, anal cancer, anal canal or rectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder or pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vaginal cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, and the like. The cancer may be any cancer, such as gastrointestinal carcinoid tumor, glioma, Hodgkin's lymphoma, hypopharyngeal cancer, kidney cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, oral pharyngeal cancer, ovarian cancer, penile cancer, pancreatic cancer, peritoneal cancer, omental mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, skin cancer, small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, uterine cancer, ureteral cancer, and bladder cancer.Preferred cancer is cervical, oral pharyngeal, anal, anal canal, anorectal, vaginal, vulva, or penile cancer.Particularly preferred cancer is COL6A3 positive cancer, such as gastrointestinal cancer and gastric cancer.

[0055] The constructs, proteins, TCRs, antibodies, polypeptides and nucleic acids of the present invention are particularly intended for use in immunotherapy, preferably adoptive T cell therapy. The administration of the compounds of the present invention may involve, for example, the infusion of T cells of the present invention into said patient. Preferably, such T cells are the patient's autologous T cells, transduced ex vivo with the nucleic acid or antigen-recognition construct of the present invention.

[0056] WO 2016 / 011210 discloses engineered cells for adoptive therapy, including NK cells and T cells, compositions containing the cells, and methods of administering them to a subject. The cells may contain engineered antigen receptors that specifically bind to antigens, such as chimeric antigen receptors (CARs) and co-stimulatory receptors.

[0057] The object of the present invention is also to a. providing a suitable host cell; b. Providing a genetic construct comprising a coding sequence encoding the antigen recognition construct according to any one of claims 1 to 4; c. introducing said genetic construct into said suitable host cell; and d. expressing said gene construct by said suitable host cell.

[0058] The method may further comprise the step of displaying the antigen recognition construct on the cell surface of the suitable host cell.

[0059] In another preferred embodiment, the genetic construct is an expression construct comprising a promoter sequence operably linked to said coding sequence.

[0060] Preferably, said antigen recognition construct is of mammalian origin, preferably of human origin.Preferred suitable host cells for use in the method of the present invention are mammalian cells, such as human cells, in particular human T lymphocytes.T cells for use in the present invention are described in detail herein above.

[0061] Also encompassed by the invention are embodiments in which the antigen recognition construct is a modified TCR, the modification being the addition of a functional domain such as a label or a therapeutically active agent. Additionally encompassed are TCRs having alternative domains, such as alternative membrane anchor domains in place of the integral transmembrane region.

[0062] Preferably, the transfection system for introducing the genetic construct into said suitable host cell is a retroviral vector system. Such systems are well known to those skilled in the art.

[0063] In one embodiment, the additional method steps of isolation and purification of the antigen recognition construct from cells, and optionally, reconstitution of the translated antigen recognition construct fragment in T cells, are also included in the invention.

[0064] In an alternative embodiment of the present invention, the T cells are provided, obtained or obtainable by a method for producing a T cell receptor (TCR) specific for tumor cells and having high avidity, as described herein above. Such T cells depend on the host cell used in the method of the present invention, e.g., a human or non-human T cell, preferably a human TCR.

[0065] The TCRs, polypeptides, proteins (including functional variants thereof), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and antibodies (including antigen-binding portions thereof) of the present invention may be isolated and / or purified. The term "isolated" as used herein means removed from its natural environment, and the term "purified" as used herein means increased purity, with "purity" being a relative term and not necessarily to be construed as absolute purity. For example, purity may be at least about 50%, may exceed 60%, 70%, 80%, 90%, 95%, or may be 100%.

[0066] The antigen recognition constructs, TCRs, polypeptides, proteins (including functional variants thereof), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and antibodies (including antigen-binding portions thereof) of the invention, hereinafter collectively referred to as "TCR materials of the invention", may be formulated into compositions, such as pharmaceutical compositions. In this regard, the invention provides pharmaceutical compositions comprising any of the antigen recognition constructs, TCRs, polypeptides, proteins, functional portions, functional variants, nucleic acids, expression vectors, host cells (including populations thereof), and antibodies (including antigen-binding portions thereof) described herein, and a pharma- ceutically acceptable carrier, excipient and / or stabilizer. Pharmaceutical compositions of the invention containing any of the TCR materials of the invention may comprise two or more TCR materials of the invention, e.g., one polypeptide and one nucleic acid, or two or more different TCRs (including functional portions and functional variants thereof). Alternatively, the pharmaceutical composition may comprise the TCR material of the invention in combination with another pharma- ceutical active agent or drug, such as, for example, a chemotherapeutic agent such as asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc. Preferably, the carrier is a pharma- ceutical acceptable carrier. For pharmaceutical compositions, the carrier may be any of those conventionally used for the particular TCR material of the invention under consideration. Such pharma-ceutical acceptable carriers are well known to those skilled in the art and are readily available to the public. Preferably, the pharma-ceutical acceptable carrier is one that has no adverse side effects or toxicity under the conditions of use.

[0067] Thus, there is also provided a pharmaceutical composition comprising any product of the invention and the TCR material of the invention, in particular any protein, nucleic acid or host cell described herein. In a preferred embodiment, the pharmaceutical composition is for immunotherapy, preferably adoptive cell therapy.

[0068] Preferably, the TCR material of the invention is administered by injection, such as, for example, intravenous injection. When the TCR material of the invention is a host cell expressing the TCR of the invention (or a functional variant thereof), the pharma- ceutically acceptable carrier for the injectable cells may include any isotonic carrier, such as, for example, saline (about 0.90% w / v NaCl in water, about 300 m Osm / L NaCl in water, or about 9.0 g NaCl per liter of water), NORMOSOL R electrolyte solution (Abbott, Chicago, IL), PLASMA-LYTE A (Baxter, Deerfield, IL), about 5% dextrose in water, or lactated Ringer's solution. In one embodiment, the pharma- ceutically acceptable carrier is supplemented with human serum albumin.

[0069] For purposes of the present invention, the amount or dose of the TCR material of the invention administered (e.g., number of cells if the TCR material of the invention is one or more cells) may be sufficient to affect, e.g., a therapeutic or prophylactic response, in a subject or animal over a reasonable time frame. For example, a dose of the TCR material of the invention should be sufficient to bind a cancer antigen or detect, treat or prevent cancer for a period of about 2 hours or more, e.g., 12-24 hours or more from the time of administration. In certain embodiments, the period may be even longer. The dose will be determined by the efficacy of the particular TCR material of the invention and the disease state of the animal (e.g., human), as well as the body weight of the animal (e.g., human) being treated.

[0070] It is contemplated that the pharmaceutical compositions, TCRs (including functional variants thereof), polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, or cell populations of the invention may be used in methods of treating or preventing cancer or COL6A3-positive precancer. The TCRs of the invention (and functional variants thereof) are believed to specifically bind to the COL6A3 antigen, such that the TCRs (or related inventive polypeptides or proteins and functional variants thereof), when expressed by a cell, can mediate an immune response against target cells expressing the COL6A3 antigen of the invention. In this respect, the present invention provides a method of treating or preventing a disease state, in particular cancer, in a mammal, comprising the step of administering to the mammal either a pharmaceutical composition as described herein, in particular an antigen recognition construct, which is a TCR (and functional variants thereof), a polypeptide, or a protein; any nucleic acid or recombinant expression vector comprising a nucleotide sequence encoding any of the TCR (and functional variants thereof) and any of the polypeptides and proteins as described herein; or any host cell or population of cells comprising a recombinant vector encoding any of the constructs (and functional variants thereof) or polypeptides or proteins of the invention as described herein, in an amount effective to treat or prevent the disease state in the mammal, wherein the disease state is cancer, preferably a COL6A3 positive cancer.

[0071] Examples of pharma- ceutically acceptable carriers or diluents useful in the present invention include SPGA, carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, stabilizers such as protein-containing agents such as bovine serum or skim milk, and buffers (e.g., phosphate buffers).

[0072] The terms "treat" and "prevent", as well as terms derived therefrom, as used herein, do not necessarily imply 100% or complete treatment or prevention. Rather, there are various degrees of treatment or prevention that one skilled in the art recognizes as having potential benefits or therapeutic effects. In this regard, the method of the present invention may provide any amount of any level of treatment or prevention of a condition in a mammal. Furthermore, the treatment or prevention provided by the method of the present invention may include treatment or prevention of one or more conditions, such as, for example, cancer, that are being treated or prevented, or symptoms of the condition. For example, treatment or prevention may include promoting tumor regression. Also, for purposes of this specification, "prevention" may include delaying the onset of a condition or symptom or the condition.

[0073] The invention also relates to methods of treating cancer comprising administering the TCRs, nucleic acids, or host cells herein in combination with at least one chemotherapeutic agent and / or radiation therapy.

[0074] a) isolating cells from said subject; b) transforming the cell with at least one vector encoding an antigen recognition construct of the invention to produce a transformed cell; c) propagating the transformed cells to generate a plurality of transformed cells; d) administering to the subject a plurality of transformed cells; Also provided is a method of treating cancer in a subject in need thereof, comprising:

[0075] a) isolating cells from a healthy donor; b) transforming the cell with a vector encoding an antigen recognition construct of the invention to produce a transformed cell; c) propagating the transformed cells to generate a plurality of transformed cells; d) administering to the subject a plurality of transformed cells; Also provided is a method of treating cancer in a subject in need thereof, comprising:

[0076] a) contacting a biological sample with an antigen recognition construct herein; b) detecting binding of the antigen recognition construct to the biological sample; Also provided is a method for detecting cancer in a biological sample, comprising:

[0077] In some embodiments, the methods for detecting cancer are performed ex vivo, in vivo, or in situ.

[0078] Also provided is a method of detecting the presence of a disease state in a mammal, the method comprising the steps of (i) contacting a sample comprising one or more cells from the mammal with a TCR (and functional variants thereof), polypeptide, protein, nucleic acid, recombinant expression vector, host cell, cell population, antibody, or antigen-binding portion thereof, of the invention, or any of the pharmaceutical compositions described herein, thereby forming a complex, and (ii) detecting the complex, wherein detection of the complex is indicative of the presence of a disease state in the mammal, the disease state being cancer, such as a COL6A3-positive malignancy.

[0079] For the present methods of detecting a disease state in a mammal, the cell sample may be a sample comprising a whole cell, a lysate thereof, or a fraction of a whole cell lysate, such as, for example, a nuclear or cytoplasmic fraction, a total protein fraction, or a nucleic acid fraction.

[0080] For detection purposes of the present invention, the contacting can be performed in vitro or in vivo with respect to a mammal. Preferably, the contacting is in vitro.

[0081] Also, detection of the complex can be performed through a number of ways known in the art.For example, the antigen recognition constructs (and their functional variants), polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, cell populations, or antibodies or TCRs, or antigen-binding portions thereof, of the present invention described herein, can be labeled with detectable labels, such as radioisotopes, fluorophores (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), enzymes (e.g., alkaline phosphatase, horseradish peroxidase), and elemental particles (e.g., gold particles).

[0082] For purposes of the methods of the invention in which a host cell or cell population is administered, the cells may be allogeneic or autologous to the mammal. Preferably, the cells are autologous to the mammal.

[0083] With regard to the aforementioned medical uses of the TCR material of the present invention, the cancers to be treated and / or diagnosed include acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, anal cancer, anal canal or rectal cancer, eye cancer, intrahepatic bile duct cancer, joint cancer, cervical cancer, gallbladder or pleural cancer, nasal cancer, nasal cavity cancer, middle ear cancer, oral cancer, vaginal cancer, vulvar cancer, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoma. The cancer may be any cancer, such as any of the following: ovariectomy, glioma, Hodgkin's lymphoma, hypopharyngeal cancer, renal cancer, laryngeal cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharyngeal cancer, non-Hodgkin's lymphoma, oropharyngeal cancer, ovarian cancer, penile cancer, pancreatic cancer, peritoneal cancer, omental mesenteric cancer, pharyngeal cancer, prostate cancer, rectal cancer, kidney cancer, skin cancer, small intestine cancer, soft tissue cancer, gastric cancer, testicular cancer, thyroid cancer, uterine cancer, ureteral cancer, and bladder cancer.Preferred cancers are cervical, oropharyngeal, anal, anal canal, anorectal, vaginal, vulvar, or penile cancer.Particularly preferred cancers are COL6A3-positive cancers, such as gastrointestinal cancer or gastric cancer.

[0084] In general, the present invention provides a method for treating a subject suffering from a tumor or a tumor disease, comprising administering an antigen recognition construct, a nucleic acid, a vector, a pharmaceutical composition and / or a host cell as disclosed by the present invention.Preferably, the subject is a subject in need of such treatment.In a preferred embodiment, the subject is a mammalian subject, preferably a human patient, suffering from a COL6A3-positive tumor or tumor disease. [Brief description of the drawings]

[0085] The present invention will be further described in the following examples with reference to the accompanying figures and sequences, but will nevertheless not be limited thereto. For the purposes of the present invention, all references cited herein are incorporated by reference in their entirety. In the figures and sequences: [Figure 1] Conversion of the TCR into a stabilized Vα / Vβ single-chain TCR (scTv) via yeast surface display. ScTv molecules displayed on the surface of transformed Saccharomyces cerevisiae EBY100 were stained with FITC-labeled anti-Vbeta1 antibody and PE-labeled HLA-A*02 / COL6A3-002 tetramer. Unmodified scTvR4P3F9 (left panel, SEQ ID NO: 22) is compared to a scTv clone with a single point mutation that stabilizes the scTv scaffold (right panel), obtained from selection of a random mutant scTv library. [Diagram 2] Figure 1 shows scTv affinity maturation via yeast surface display. Stabilized scTv molecules with and without affinity matured CDR1β were stained with HLA-A*02 tetramers containing COL6A3-002 (SEQ ID NO: 1) and counterstained with a mixture of HLA-A*02 tetramers containing nine peptides with high sequence similarity to COL6A3-002 (SEQ ID NO: 28-36). A stabilized scTv (SEQ ID NO: 27) with the non-mature β-chain CDR1 sequence RSGDLS (SEQ ID NO: 13) is compared to a scTv clone with affinity matured β-chain CDR1 sequences AMDHPY (SEQ ID NO: 40) and ARWHRN (SEQ ID NO: 39). [Figure 3-1]FIG. 1 shows size exclusion chromatography elution profiles of anti-CD3 Fab-scTv R4P3F9S fusion variants 75-1 to 75-25. [Figure 3-2] Same as above [Figure 4-1] Figure 1 shows the HLA-A*02 / COL6A3-002 binding kinetics of anti-CD3 Fab-scTv R4P3F9S fusion variants 75-1 to 75-25 as measured by biolayer interferometry. Analytical concentrations of HLA-A*02 / COL6A3-002 are shown. [Figure 4-2] Same as above [Figure 5-1] Binding analysis of anti-CD3 Fab-scTv R4P3F9S fusion variants 75-1 to 75-25 measured via biolayer interferometry (BLI). 1 μM HLA-A*02 in complex with the indicated analogous peptides was analyzed. [Figure 5-2] Same as above [Figure 6] Figure 1 shows a comparison of the binding kinetics of different anti-CD3 Fab-scTv R4P3F9S fusion variants to HLA-A*02 / COL6A3-002 and HLA-A*02 / COL6A1-001 (SEQ ID NO: 30). Assayed concentrations of Fab-scTv molecules are indicated. [Figure 7] Staining of human CD8+ T cells expressing mature R4P3F9 TCR variants with PE-labeled HLA-A*02 / COL6A3-002 tetramers is shown. For control purposes, no TCR (mock) or 1G4 TCR specific for NYESO1-001 was expressed and stained with PE-labeled HLA-A*02 / NYESO1-001 tetramers were used. [Figure 8] Figure 1 shows IFN-γ release of mature R4P3F9 TCR mutant expressing human CD8+ T cells in response to COL6A3-002. For control purposes, no TCR (mock) or 1G4 TCR specific for NYESO1-001 was expressed. IFN-γ release was determined by ELISA after co-culture of electroporated CD8+ T cells with T2 cells loaded with serial dilutions of COL6A3-002. [Figure 9-1]Figure 1 shows IFN-γ release of mature R4P3F9 TCR mutant expressing human CD8+ T cells in response to COL6A3-002 and different similar peptides. For control purposes, no TCR (mock) or 1G4 TCR specific for NYESO1-001 was expressed. IFN-γ release was determined by ELISA after co-culture of electroporated CD8+ T cells with T2 cells loaded with 10 μM COL6A3-002 or similar peptides. [Figure 9-2] Same as above [Figure 9-3] Same as above [Figure 9-4] Same as above [Figure 10] Staining of human CD8+ T cells expressing mature R4P3F9 TCR variant with PE-labeled peptide HLA-A*02 tetramer is shown. For control purposes, no TCR (mock) or 1G4 TCR specific for NYESO1-001 was expressed and stained with PE-labeled HLA-A*02 / NYESO1-001 tetramer was used. [Figure 11] Figure 1 shows IFN-γ release of mature R4P3F9 TCR mutant expressing human CD8+ T cells in response to COL6A3-002 or COL6A1-001. For control purposes, no TCR (mock) or 1G4 TCR specific for NYESO1-001 was expressed. IFN-γ release was determined by ELISA after co-culture of electroporated CD8+ T cells with T2 cells loaded with serial dilutions of COL6A3-002 or COL6A1-001. [Figure 12] Figure 1 shows IFN-γ release of primary human CD8+ T cells expressing the R4P3F9 TCR variant upon co-culture with different tumor cell lines, SF539, SW982, and Hs840. T cells present the target peptide at different levels. MCF-7 cells do not present the target peptide. As a control, effector cells without exogenous TCR were analyzed together with cells of the TCR of interest. IFN-γ release was determined by ELISA. * marks off-scale data points.

[0086] Table 1: Peptide sequences of the invention (positions according to IMGT numbering: (Francois Ehrenmann, Patrice Duroux, Chantal Ginestoux; Protein presentation: Human (Homo sapiens) TRAV; IMGT Repertoire. IMGT 登録商標 , the international ImMunoGenetics information system 登録商標 http: / / www.imgt.org.; Creation date: 16 / 03 / 2011. Version: 03 / 06 / 2016; Francois Ehrenmann, Patrice Duroux, Chantal Ginestoux; Protein display: Human (Homo sapiens) TRBV; IMGT Repertoire. IMGT 登録商標 , the international ImMunoGenetics information system 登録商標 http: / / www.imgt.org.; Creation date: 16 / 03 / 2011. Version: 03 / 06 / 2016). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] EXAMPLES

[0087] Natural cell receptors (TCRs) for cancer antigens often have lower affinity when compared to TCRs targeting viral antigens, which may be one possible explanation for tumor immune escape (Aleksic et al. 2012). It is therefore desirable to have higher affinity TCR variants designed for use as antigen recognition constructs in adoptive cell therapy or as recognition modules for soluble approaches, i.e. using bispecific molecules (Hickman et al. 2016). The present invention therefore relates to the modification and optimization of the naturally occurring T cell receptor R4P3F9 (SEQ ID NO: 2 and 10) that targets the tumor-associated peptide COL6A3-002 (SEQ ID NO: 1) with an affinity of about 60 μM (DE 102016115246).

[0088] Example 1: Generation of stable scTv In the present invention, the previously investigated TCR R4P3F9 (SEQ ID NO: 2 and 10) was converted into a single-chain TCR construct (scTv, SEQ ID NO: 22) by combining the variable α (SEQ ID NO: 4) and β (SEQ ID NO: 12) domains with the respective constant domains (SEQ ID NO: 9 and 17) and the appendage of an appropriate glycine-serine linker sequence for maturation via yeast surface display. The corresponding DNA sequences were synthesized and transformed into Saccharomyces cerevisiae EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2-delta200 his3-delta200 pep4::HIS3 prbd1.6R can1 GAL) (ATCC® MYA-4941™) along with a yeast display vector containing a leader sequence based on pCT302 and the Aga2p yeast mating protein (SEQ ID NO:20) (Boder et al. 2000). The fusion protein (SEQ ID NO: 19) obtained after homologous recombination in yeast contains the N-terminal leader peptide of the Aga2p protein, involved in the presentation of the protein of interest (Boder et al. 1997), linker sequences for expression control (SEQ ID NOs: 21 and 23), and a short peptide tag containing the protein of interest, i.e., scTvR4P3F9 (SEQ ID NO: 22) or a variant thereof. Transformation was carried out as described in DE 102016121899, and up to 10 9 Yeast clones were obtained. The library was generated through a random mutation PCR approach spanning the entire gene sequence of scTv R4P3F9.

[0089] HLA-A * The selection process for yeast clones best expressing scTvs that selectively bind COL6A3-002 in the context of COL6A3-002 was performed essentially as described in Smith et al., 2015. To confirm high expression and correct conformation of the scTv R4P3F9 variant displayed on the yeast surface, we used the HLA-A *Anti-Vβ1 (Beckman Coulter, clone BL37.2) antibody was used together with 02 / COL6A3-002 tetramer (Figure 1). ScTv conversion by yeast surface display revealed two important stabilizing mutations in the framework region along with the original CDR sequences for proper presentation of scTv on the cell surface, namely bQ43K (SEQ ID NO: 24) and bL72S (SEQ ID NO: 25), both located on the β chain. Furthermore, during stable maturation, position 29 (SEQ ID NO: 5) of CDR1 of the α chain was converted from glycine to arginine (CDRa1 mutant 1, SEQ ID NO: 26), which resulted in improved tetramer binding.

[0090] Example 2: Affinity maturation of stabilized scTvs HLA-A * To generate scTv molecules with higher binding affinity to COL6A3-002 / COL6A3-002, the previously identified stabilized scTv R4P3F9S scaffold (SEQ ID NO: 27), expressing the stabilizing mutations aG29R, bQ43K, and bL72S, was used to modify CDRb1 (SEQ ID NO: 13). CDRb1 residues were randomized by using degenerate DNA oligoprimers essentially as previously described (Smith et al., 2015). The resulting DNA library was transformed as described in Example 1. To preserve scTv binding selectivity, a HLA-A library was created comprising peptides derived from normal tissues (SEQ ID NOs: 28-36) that show high sequence similarity to the COL6A3-002 peptides. * Negative selection was employed against the 02 tetramer.

[0091] To select for the selective scTv R4P3F9S variant with enhanced affinity, we used HLA-A *Diminishing concentrations of COL6A3-002 / COL6A3-002 tetramer were used for each selection round. After three selection rounds, single scTv clones were isolated and sequenced, resulting in various affinity matured CDRb1 sequences (SEQ ID NOs: 37-49). The scTvs with matured CDRb1 sequences could show strong improvement in COL6A3-002 binding, while no binding of the nine similar peptides was observed, thus retaining the selectivity of COL6A3-002 binding (Figure 2).

[0092] Example 3: Generation of bispecific antibody-scTv fusion proteins HLA-A * Stabilized and affinity matured scTvs against 02 / COL6A3-002 can be expressed fused to antibody moieties against CD3, allowing tumor-specific retargeting and T cell activation, regardless of their native specificity. We generated a bispecific antibody-TCR fusion protein comprising an anti-CD3Fab (UCHT1) heavy chain (SEQ ID NO:51) fused to the scTv R4P3F9S mutant (SEQ ID NO:50, 64, 65, and 66) and an anti-CD3Fab (UCHT1) light chain (SEQ ID NO:52). The resulting Fab-scTv fusion protein has a molecular weight of approximately 75 kDa. Based on the different CDR1 sequences of scTv R4P3F9S α-chain (SEQ ID NO: 5 and 26) and β-chain (SEQ ID NO: 13 and 37-49), different Fab-scTv fusion variants (75-1 to 75-25, Table 2) were expressed in transiently transfected ExpiCHO cells as recommended by the manufacturer. Proteins were purified by protein L and size-exclusion chromatography. All fusion variants could be produced in homogeneously formed heterodimers of the expected size analyzed by size-exclusion chromatography (Figure 3), with yields ranging from 80 μg to 1 mg (Table 2).

[0093] [Table 2]

[0094] Example 4: Fab-scTv fusion proteins that bind to COL6A3-002 and similar peptides HLA-A with COL6A3-002 or different similar peptides * The binding affinity of the anti-CD3-scTv R4P3F9S fusion protein to the HLA-A 02 monomer was measured by biolayer interferometry. Measurements were performed on an Octet RED384 system using the settings recommended by the manufacturer. Briefly, HLA-A 02 monomer was detected by the following antibody: * Purified Fab-scTv molecules were loaded onto a biosensor (FAB2G) prior to analysis of serial dilutions of 02 / COL6A3-002. Up to 40-fold increased binding affinity was observed for Fab-scTv variants with mature CDRa1 and / or CDRb1 sequences compared to variants 75-1 and 75-24, which comprise wild-type CDRa1 and wild-type CDRb1 (Table 3, Figure 4). HLA-A * To assess the selectivity of binding to HLA-A 02 / COL6A3-002, * Purified Fab-scTv molecules loaded onto a FAB2G biosensor were screened for binding to 1 μM analogous peptides (SEQ ID NO: 28-36) complexed with 02. HLA-A bound by most of the Fab-scTv variants containing mature CDRa1 (SEQ ID NO: 26) was * With the exception of 02 / COL6A1-001 (SEQ ID NO: 30), the Fab-scTv variants did not show binding to similar peptides (Figure 5), which suggests high binding selectivity. For some Fab-scTv variants, the HLA-A binding was confirmed by loading biotinylated peptide-HLA complexes onto a biosensor (SA) and analyzing a dilution series of the Fab-scTv variants. * 02 / COL6A3-002 and HLA-A * The therapeutic window during binding of 02 / COL6A1-001 was investigated. The variant 75-10, comprising the mature CDRa1 (SEQ ID NO: 26) and wild-type CDRb1 (SEQ ID NO: 13) sequences, binds to HLA-A * HLA-A over 02 / COL6A1-001 *02 / COL6A3-002 showed an 8-fold increase in binding affinity, whereas up to a 57-fold increase in binding affinity was detected for Fab-scTv variant 75-13 comprising the mature CDRb1 (SEQ ID NO: 39), claiming an improved therapeutic window (Table 4, Figure 6).

[0095] [Table 3]

[0096] [Table 4]

[0097] Example 5: Use of affinity matured TCRs for cell expression Modification of T cells to express TCRs that recognize tumor-specific peptide HLA is a promising alternative to redirect T cells to cancer cells. * The identified CDRa1 and CDRb1 mutant sequences were grafted onto the parent TCRR4P3F9 (SEQ ID NOs: 2 and 10) because they could improve cell binding to COL6A3-002. The resulting mutant TCR variants (C-1 to C-18, Table 5) were shown to bind to human CD8 T cells after electroporation of the respective mRNAs generated by in vitro transcription of the PCR amplified DNA constructs. + For control purposes, the 1G4 TCR (SEQ ID NO: 53 and 57) against the NYESO1-001 peptide (SEQ ID NO: 61) was expressed. + After overnight incubation of T cells, PE-labeled HLA-A * 02 / COL6A3-002 tetramer or HLA-A * The expression of the introduced TCR variants was analyzed by staining with 02 / NYESO1-001 tetramer. The parental TCR variant C-1 is HLA-A *CD8 T cells expressing different mature R4P3F9 TCR variants showed only minimal staining with COL6A3-002 / COL6A3-002 tetramers, whereas R4P3F9 TCR variants C-2 to C-18 with mature CDRa1 and / or CDRb1 showed increased tetramer staining (Figure 7). CD8 T cells expressing different mature R4P3F9 TCR variants were assayed by determining the levels of IFN-γ released upon co-culture with T2 cells (20,000 cells / well) loaded with either a dilution series of COL6A3-002 (SEQ ID NO: 1) or 10 μM COL6A3-002 and analogous peptides (SEQ ID NOs: 28 to 36). + The functional activation of T cells (20,000 cells / well) was investigated. Compared to the parental R4P3F9 TCR variant C-1, the mature TCR variants C-2 to C-18 showed increased IFN-γ release, reaching maximum concentrations already at lower peptide concentrations (Figure 8). As expected, no IFN-γ release was observed in T cells expressing no TCR or the 1G4 control TCR specific for NYESO1-001. To analyze the selectivity of the mature R4P3F9 TCR variants' recognition of COL6A3-002, IFN-γ release in response to T2 cells loaded with different analogous peptides (SEQ ID NOs: 28 to 36) was analyzed, revealing different selectivity profiles for the mature R4P3F9 TCR variants. Most interestingly, TCR variants C-5 (SEQ ID NO: 62 and 2) and C-14 (SEQ ID NO: 62 and 63), which comprise the same mature CDRb1 (SEQ ID NO: 40), do not show any cross-reactivity to COL6A1-001 or other similar peptides (Figure 9), making the affinity matured R4P3F9 TCR variants C-5 and C14 the most promising candidates for cellular TCR-based tumor targeting.

[0098] [Table 5]

[0099] Example 6: Windows of COL6A3-002 and COL6A1-001 recognition of cellular TCR variants Cellular expression and analysis of R4P3F9 variants were performed as described above. According to previous experiments (Figure 7), PE-labeled HLA-A of T cells expressing R4P3F9 TCR variants C-2 to C-18 were * Staining with 02 / COL6A3-002 tetramer was increased compared to the parental TCR C-1. Furthermore, TCR variants C-12 and C-17 were associated with HLA-A * Expression of the mature R4P3F9 mutant induced increased CD8 binding to T2 cells loaded with a dilution series of COL6A3-002 (SEQ ID NO: 1) (Figure 10). + Improved functional activation of T cells with 5-90-fold lower EC compared to parental TCRC-1 50 The lowest EC values ​​were achieved (Figure 11, Table 6). 50 Again, TCR variants C-5 (SEQ ID NO: 62 and 2) and C-14 (SEQ ID NO: 62 and 63), which comprise the same mature CDRb1 (SEQ ID NO: 40), showed no cross-reactivity to COL6A1-001, whereas the other variants showed no cross-reactivity to EC 50 window (COL6A3-002 vs. COL6A1-001), demonstrating a 5-fold stronger recognition.

[0100] [Table 6]

[0101] Example 7: Efficacy of mature R4P3F9 variants C-5 and C-14 against tumor cell lines Cellular expression and analysis of R4P3F9 variants was performed as described above.

[0102] Expression of mature R4P3F9 mutants C-5 (SEQ ID NO: 62 and 2) and C-14 (SEQ ID NO: 62 and 63) increased CD8 expression in response to COL6A3-002 (SEQ ID NO: 1)-presenting tumor cell lines compared to the parental TCR C-1 (Figure 12). + The tumor cell lines used in this study present different amounts of the target peptide. SF539 cells express approximately 4000 copies of HLA-A per cell.* SW982 cells carry approximately 460 copies of 02 / COL6A3-002 per cell. While the parental TCR C-1 did not mediate potent T cell activation upon co-culture with target-positive cell lines, the TCR variant C-14 showed a stronger improvement in functional activation than the TCR variant C-5. These data support the EC 50 Consistent with the improvement (Table 6), the target-negative tumor cell line MCF-7 was not recognized by any of these TCRs.

[0103] References: Aleksic et al. 2012: Different affinity windows for virus and cancer-specific T-cell receptors-implications for therapeutic strategies, Eur J Immunol. 2012 Dec;42(12):3174-9; Hickman et al. 2016: Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies, J Biomol Screen. 2016 Sep;21(8):769-85; Boder and Wittrup 2000: Yeast surface display for directed evolution of protein expression, affinity, and stability, Methods Enzymol. 2000;328:430-44; Boder and Wittrup 1997: Yeast surface display for screening combinatorial polypeptide libraries, Nat Biotechnol. 1997 Jun;15(6):553-7; Smith et al. 2015: T Cell Receptor Engineering and Analysis Using the Yeast Display Platform, Methods Mol Biol. 2015;1319:95-141; DE102016121899.5 DE102016115246

Claims

1. An antigen recognition construct comprising: a first domain comprising three complementarity determining regions (CDRs) comprising the amino acid sequences set forth in SEQ ID NOs: 5 (CDRa1), 6 (CDRa2), and 7 (CDRa3); and a second domain comprising three complementarity determining regions (CDRs) comprising the amino acid sequences set forth in SEQ ID NOs: 13 (CDRb1), 14 (CDRb2), and 15 (CDRb3), wherein at least one of the complementarity determining regions is a) SEQ ID NO: 26 (CDRa1 variant 1) and SEQ ID NOs: 37-49 (CDRb1-mut1 to CDRb1-mut13), and b) an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and a variant sequence comprising at least one of SEQ ID NOs: 37-49; wherein the at least one amino acid sequence contains one, two, or three amino acid substitutions.

2. The antigen recognition construct of claim 1, wherein the antigen recognition construct is stable and can specifically and / or selectively bind, particularly in the context of MHC, to a COL6A3 antigen peptide comprising the amino acid sequence set forth in SEQ ID NO:

1.

3. The antigen recognition construct according to claim 1 or 2, wherein the antigen recognition construct is an antibody or a derivative thereof, such as a bispecific molecule or fragment, or a T cell receptor (TCR) or a derivative thereof, such as a bispecific molecule or fragment.

4. The antigen recognition construct according to any one of claims 1 to 3, wherein the first domain is a part of a TCR α or γ chain, and / or the second domain is a part of a TCR β or δ chain.

5. A nucleic acid encoding the antigen recognition construct according to any one of claims 1 to 4, or a nucleic acid vector comprising said nucleic acid.

6. 10. A recombinant host cell comprising an antigen recognition construct according to any one of claims 1 to 4, or a nucleic acid or vector according to claim 5, which is preferably a) a lymphocyte, such as a T lymphocyte, or a T lymphocyte progenitor cell, e.g. a CD4+ or CD8+ T cell, or b) a non-lymphocyte, such as a Chinese hamster ovary (CHO) cell.

7. A pharmaceutical composition comprising an antigen recognition construct according to any one of claims 1 to 4, or a nucleic acid or vector according to claim 5, or a host cell according to claim 6, and a pharmaceutically acceptable carrier, diluent, stabilizer and / or excipient.

8. a. providing a suitable host cell; b. Providing a genetic construct comprising a coding sequence encoding the antigen recognition construct of any one of claims 1 to 4; c. introducing said genetic construct into said suitable host cell; d. expressing said genetic construct by said suitable host cell; A method for producing a COL6A3-specific antigen-recognizing construct according to any one of claims 1 to 4, comprising:

9. 9. The method of claim 8, further comprising isolating and purifying the antigen recognition construct from the suitable host cell, and optionally reconstituting the antigen recognition construct in a T cell.

10. An antigen recognition construct according to any one of claims 1 to 4, a nucleic acid or vector according to claim 5, a host cell according to claim 6, or a pharmaceutical composition according to claim 7, for use in medicine.

11. An antigen recognition construct according to any one of claims 1 to 4, a nucleic acid or vector according to claim 5, a host cell according to claim 6, or a pharmaceutical composition according to claim 7, for use in the diagnosis, prevention, and / or treatment of a proliferative disease such as cancer.

12. The antigen recognition construct of any one of claims 1 to 4, the nucleic acid or vector of claim 5, the host cell of claim 6, or the pharmaceutical composition of claim 7 for use according to claim 11, wherein the cancer is selected from cancers in which COL6A3 is overexpressed or mutated and / or in which a tumor-associated antigen derived from COL6A3 is presented, such as colorectal cancer, colon cancer, liver cancer, ovarian cancer, and gastric cancer.

13. The antigen recognition construct according to any one of claims 1 to 4, wherein the mutant sequence is a combination of the first and second amino acid sequences provided by substituting one, two, or three amino acids in the first sequence with corresponding one, two, or three amino acids in the second sequence.

14. The antigen recognition construct of claim 13, wherein the variant sequence is a combination of the first and second amino acid sequences provided by substituting one, two, or three consecutive amino acids in the thirteenth sequence with the corresponding one, two, or three consecutive amino acids in the second sequence.

15. The antigen recognition construct according to any one of claims 1 to 4 and 13 to 14, wherein the mutant sequence of (b) contains at least one conservative amino acid substitution compared to at least one amino acid sequence of (a).

16. The antigen recognition construct according to any one of claims 1 to 4, wherein at least one of the complementarity determining regions is substituted with SEQ ID NO: 40, and SEQ ID NO: 40 contains one, two, or three amino acid substitutions.

17. The antigen recognition construct according to any one of claims 1 to 4, wherein at least one of the complementarity determining regions is substituted with SEQ ID NO:

40.

18. The antigen recognition construct according to any one of claims 1 to 4, comprising a variant selected from the group consisting of 75-1 to 75-25 in Table 2 and C-1 to C-18 in Table 5.

Citation Information

Patent Citations

  • Arrays with cleavable linkers

    WO2006002382A2